|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
The 5'-methylthioadenosine (MTA) cycle-participating human acireductone dioxygenase 1 (ADI1) has been implicated as a tumor suppressor in prostate cancer, yet its role remains unclear in hepatocellular carcinoma (HCC).
|
30858354 |
2019 |
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
ARD-266 is capable of reducing the AR protein level by >95% in these AR+ prostate cancer cell lines and effectively reduces AR-regulated gene expression suppression.
|
31804827 |
2019 |
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.
|
30629437 |
2019 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Collectively, these observations argue that ADI1 may check prostate cancer progression through apoptosis and that this activity does not require metal binding.
|
17786183 |
2007 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
CTD_human |
Collectively, these observations argue that ADI1 may check prostate cancer progression through apoptosis and that this activity does not require metal binding.
|
17786183 |
2007 |
|
Prostatic Neoplasms
|
0.310 |
AlteredExpression
|
group |
LHGDN |
Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.
|
17786183 |
2007 |
|
Prostatic Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.
|
17786183 |
2007 |
|
Prostatic Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.
|
17786183 |
2007 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The 5'-methylthioadenosine (MTA) cycle-participating human acireductone dioxygenase 1 (ADI1) has been implicated as a tumor suppressor in prostate cancer, yet its role remains unclear in hepatocellular carcinoma (HCC).
|
30858354 |
2019 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ARD-266 is capable of reducing the AR protein level by >95% in these AR+ prostate cancer cell lines and effectively reduces AR-regulated gene expression suppression.
|
31804827 |
2019 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
ARD-69 is capable of reducing the AR protein level by >95% in these prostate cancer cell lines and effectively suppressing AR-regulated gene expression.
|
30629437 |
2019 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Collectively, these observations argue that ADI1 may check prostate cancer progression through apoptosis and that this activity does not require metal binding.
|
17786183 |
2007 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
A single dose of ARD-69 effectively reduces the level of AR protein in xenograft tumor tissue in mice.
|
30629437 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The 5'-methylthioadenosine (MTA) cycle-participating human acireductone dioxygenase 1 (ADI1) has been implicated as a tumor suppressor in prostate cancer, yet its role remains unclear in hepatocellular carcinoma (HCC).
|
30858354 |
2019 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
CIGB-814, originally named as E18-3 APL1 or APL1 in preclinical experiments, is a novel therapeutic peptide candidate for Rheumatoid Arthritis (RA).
|
28595106 |
2017 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
APL-1 is an altered peptide ligand derived from a novel CD4 + T cell epitope of human heat-shock protein of 60 kDa (HSP60), an autoantigen involved in the pathogenesis of rheumatoid arthritis (RA).
|
27160252 |
2017 |
|
Rheumatoid Arthritis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the ability of APL-1 in inducing apoptosis in PBMCs from RA patients, who were classified as active or inactive according to their DAS28 score.
|
24177275 |
2013 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more ADI1 than tumors, suggesting a suppressive role for ADI1 in prostate cancer.
|
17786183 |
2007 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Consistently, MTCBP-1-expressing cells show decreased ability to invade in vitro and metastasize in vivo.
|
30487181 |
2019 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Finally, we show that acn-1(RNAi) enhances the let-7-suppressing phenotypes caused by loss of apl-1, a homologue of the Alzheimer's disease-causing amyloid precursor protein (APP), while significantly disrupting the expression of apl-1 during the L4 larval stage.
|
28933985 |
2017 |
|
Alzheimer's Disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our work places apl-1 in a developmental timing pathway and may provide new insights into the time-dependent progression of AD.
|
18262516 |
2008 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Additionally, we demonstrated that transfection of SKOV3 cells with S2cDNA or ARD cDNA results in an upregulation of HA-mediated tumor cell migration.
|
10737894 |
2000 |
|
HIV Infections
|
0.010 |
GeneticVariation
|
group |
BEFREE |
PrEP was associated with decreased risk of HIV infection vs placebo or no PrEP after 4 months to 4 years (11 trials; relative risk [RR], 0.46 [95% CI, 0.33-0.66]; I2 = 67%; absolute risk reduction [ARD], -2.0% [95% CI, -2.8% to -1.2%]).
|
31184746 |
2019 |
|
Liver neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The methionine salvage pathway-involving ADI1 inhibits hepatoma growth by epigenetically altering genes expression via elevating S-adenosylmethionine.
|
30858354 |
2019 |
|
Pancreatic Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further, we observe an inverse correlation between MTCBP-1 and MT1-MMP expression both in cultured cell lines and human pancreatic tumors.
|
30487181 |
2019 |